BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Nimotuzumab: Completed Phase II enrollment

YM BioSciences disclosed in its fiscal 2Q11 earnings that partner Daiichi Sankyo completed enrollment in a Phase II trial evaluating nimotuzumab in combination with radiation therapy, cisplatin and vinorelbine in patients with stage III NSCLC. Nimotuzumab is available in the U.S. on a compassionate use basis to treat pediatric glioma and has Orphan Drug designation in the U.S....

Read the full 268 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >